Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Liver Transplantation Center and Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
J Surg Res. 2023 Mar;283:1091-1099. doi: 10.1016/j.jss.2022.11.039. Epub 2022 Dec 15.
Tumor necrosis has been associated with poor prognosis in hepatocellular carcinoma (HCC) patients undergoing liver resection (LR). However, more evidence is needed to clarify this issue.
Patients who underwent upfront LR between 2010 and 2018 for newly diagnosed HCC without undergoing neoadjuvant therapy were enrolled in this retrospective study. Tumor necrosis was classified as present or absent according to retrospective examinations. The association between tumor necrosis, pathologic characteristics, overall survival (OS), and recurrence-free survival (RFS) were analyzed.
Among 756 patients who underwent LR for HCC, tumor necrosis was present in 279 (36.9%) patients. Compared with patients without tumor necrosis, patients with tumor necrosis had higher proportions of tumors sized >5.0 cm (P < 0.001), multiple tumors (P < 0.001), microvascular or macrovascular invasion (P < 0.001), poorly differentiated or undifferentiated tumors (P < 0.001), and T stage 3 or 4 (P < 0.001) on pathological examination. The presence of tumor necrosis was associated with worse OS and RFS compared with the absence of tumor necrosis: 5-y OS was 56% versus 78% (P < 0.001); 5-y RFS was 42% versus 55% (P < 0.001). In multivariate analysis, the presence of tumor necrosis was an independent factor associated with worse OS (hazard ratio: 1.956; 95% confidence interval: 1.409-2.716; P < 0.001) and RFS (hazard ratio: 1.422; 95% confidence interval: 1.085-1.865; P = 0.011).
Tumor necrosis was associated with worse OS and RFS among patients who underwent LR for HCC.
肿瘤坏死与接受肝切除术 (LR) 的肝细胞癌 (HCC) 患者的预后不良相关。然而,需要更多的证据来阐明这个问题。
本回顾性研究纳入了 2010 年至 2018 年间未经新辅助治疗而行初次 LR 治疗的新诊断 HCC 患者。根据回顾性检查,将肿瘤坏死分为存在或不存在。分析肿瘤坏死与病理特征、总生存期 (OS) 和无复发生存期 (RFS) 之间的关系。
在 756 例行 LR 治疗 HCC 的患者中,有 279 例 (36.9%) 患者存在肿瘤坏死。与无肿瘤坏死的患者相比,有肿瘤坏死的患者肿瘤直径>5.0cm 的比例更高 (P<0.001)、多个肿瘤的比例更高 (P<0.001)、微血管或大血管侵犯的比例更高 (P<0.001)、分化差或未分化肿瘤的比例更高 (P<0.001)、以及 T 分期为 3 或 4 期的比例更高 (P<0.001)。与无肿瘤坏死相比,有肿瘤坏死与较差的 OS 和 RFS 相关:5 年 OS 为 56%比 78% (P<0.001);5 年 RFS 为 42%比 55% (P<0.001)。多变量分析显示,肿瘤坏死的存在是与较差 OS 相关的独立因素 (危险比:1.956;95%置信区间:1.409-2.716;P<0.001) 和 RFS (危险比:1.422;95%置信区间:1.085-1.865;P=0.011)。
在接受 LR 治疗 HCC 的患者中,肿瘤坏死与较差的 OS 和 RFS 相关。